Vulvodynia Clinical Trial
Official title:
A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
Verified date | April 2016 |
Source | University of Tennessee |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Specific aims of this project are to (1) test the prediction that pain from tampon insertion (primary outcome measure) is lower in PVD patients when treated with gabapentin compared to when treated with placebo. Secondary outcome measures include intercourse pain and 24-hour pain and (2)perform a mechanism-based analysis of gabapentin effectiveness, and to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more specific treatment options.
Status | Completed |
Enrollment | 230 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Women who are 18 years of age and older, as long as no vaginal atrophy is present. If vaginal atrophy is present, then topical hormone replacement can be provided for a minimum of 6 weeks and then she must be re-screened to be eligible, 2. Greater than 3 continuous months of insertional (entryway) dyspareunia, pain to touch, or both with tampon insertion (modified 'Friedrich's Criteria', and 3. an average pain level of "4" or greater on the 11-point tampon test (0 = no pain at all; 10 = worse pain ever) during the 2-week screening period must be exhibited. (One tampon will be inserted each week). 4.) Must report pain with the "Tampon Insertion Pain" Test at visit 1 Exclusion Criteria: 1. Other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, or atrophic vaginitis (presence of a maturation index) 2. previous vestibulotomy 3. active vaginal infection (positive Affirm ™ VPIII microbial identification test) 4. pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study 5. any unstable medical condition, including renal impairment (creatinine clearance of =60 mL/min, BUN > 30mg/dL, serum creatinine > 2 mg/dL), significant hematological disease (leukopenia [WBC < 3.0 x 10-3µl, leukocytosis [WBC >20.0 x 10-3µl], neutropenia [ABS < 1.50 x 10-3 µl, <20%]), (thrombocytopenia [platelets < 100,000 µl], anemia [HCT < 27%, HBG <8 g/dL, RBC <3 x 10-6]), cardiovascular disease (cardiac conduction disturbance, CHF, hypertension [140/90]), hepatic insufficiency (serum AST, ALT, or ALP = 3 times upper limit of normal), neurological disorder (seizures, syncopal episodes, peripheral neuropathy, severe pain other than that caused by vulvodynia), autoimmune disease, or respiratory illness 6. psychiatric disorder, including history of major depressive disorder or substance abuse disorder within the past 6 months, a score of > 12 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS), indicting a major depressive episode (35,36), a serious risk of suicide, or lifetime history of psychosis, hypomania or mania 7. multiple allergies 8. use of benzodiazepines, opiates, muscle relaxants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or CNS stimulants (including methylphenidate, amphetamine dextroamphetamine) within 2 weeks of randomization and during the study 9. use of certain herbal agents within 2 weeks of randomization and during the study, including ginkgo biloba, evening primrose, St. John's Wort, Valerian, kava kava) 10. topical lidocaine use 11. Subjects, who are diagnosed with coexisting vaginismus, fibromyalgia and/or interstitial cystitis, must have greater vulvar pain than their coexisting conditions or they will not be eligible for study participation 12. Subject who have previously taken gabapentin or Lyrica but discontinued the medication due to side effects are not eligible 13. Subjects with active infections (Candida, BV, trichomonas, chlamydia, GC and HSV via Affirm/culture) must be treated and re-screened to eligible for participation 14. Subjects with 10% or greater parabasal cells and/or vaginal atrophy can be provided with topical hormone replacement for a minimum of 6 weeks and then must be re-screened to be eligible 15. Subjects who have had gastric bypass surgery are ineligible for study participation due to drug absorption problems 16. HPV/abnormal Pap is not exclusionary 17. Ongoing counseling and/or physical therapy is not exclusionary 18. Subjects who report signs of mixed Vulvodynia (spontaneous/provoked, localized, generalized) during prescreening will not be excluded |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Research Center | Memphis | Tennessee |
United States | Rutgers - Robert Wood Johnson Medical School | New Brunswick | New Jersey |
United States | University of Rochester School of Medicine and Dentistry | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
University of Tennessee | University of Tennessee Health Science Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tampon Test Pain Intensity | Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days). | Week 6 for each treatment arm | |
Secondary | Coital Pain | Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm. | Week 6 of each treatment arm | |
Secondary | Vulvodynia Pain | Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged. | Week 6 for each treatment arm |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05478746 -
Effects of Flourish HEC on Localized Provoked Vulvodynia
|
N/A | |
Completed |
NCT02404961 -
Women's Health Study: Immunological Factors and Risk of Vulvodynia
|
||
Completed |
NCT00751010 -
Relationship: Interstitial Cystitis & Vulvodynia-Part 2
|
N/A | |
Completed |
NCT00607490 -
A Randomized Clinical Trial for Women With Vulvodynia
|
N/A | |
Recruiting |
NCT03640624 -
Multidisciplinary Treatment of Chronic Vulvar Pain
|
N/A | |
Recruiting |
NCT05343182 -
Vestibulectomy Surgical Techniques Comparison Study
|
N/A | |
Recruiting |
NCT05518630 -
An Investigation of Nomothetic Versus Idiographic Assessment in Chronic Pain
|
||
Recruiting |
NCT05597358 -
Efficacy of High Intensity Laser for Provoked Vestibulodynia
|
N/A | |
Completed |
NCT01304589 -
Savella in Treatment for Provoked Vestibulodynia
|
Phase 3 | |
Completed |
NCT00590590 -
Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort
|
Phase 2 | |
Recruiting |
NCT06138171 -
Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia
|
||
Completed |
NCT01996384 -
Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
|
Phase 1 | |
Completed |
NCT01664962 -
Search for Genetic Basis of Vulvodynia
|
N/A | |
Recruiting |
NCT05955313 -
Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia
|
Phase 2 | |
Completed |
NCT02773641 -
Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia
|
Phase 3 | |
Completed |
NCT00501774 -
A Search for Helicobacter Pylori in Localized Vulvodynia
|
N/A | |
Completed |
NCT04057755 -
Botulinum Toxin A as a Treatment for Provoked Vestibulodynia
|
Phase 3 | |
Terminated |
NCT04016467 -
Effect of Spinal Manipulation on Vulvar Pain
|
N/A | |
Completed |
NCT01935063 -
Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia
|
N/A | |
Completed |
NCT02809612 -
An Internet-based Information Platform for Vulvodynia Patients
|
N/A |